Company Filing History:
Years Active: 2022
Title: J Fraser Glickman: Innovator in Therapeutic Agents
Introduction
J Fraser Glickman is a notable inventor based in New York, NY. He has made significant contributions to the field of therapeutic agents, particularly in the context of autoimmune diseases. His work focuses on the development of compounds that inhibit human cGAS, which plays a crucial role in the immune response.
Latest Patents
Glickman holds a patent for "Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS - 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones." This patent discloses compounds that are effective inhibitors of human cGAS in interferon-producing cell types. These compounds are particularly useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
Career Highlights
Throughout his career, Glickman has worked with prestigious institutions such as The Rockefeller University and Memorial Sloan Kettering Cancer Center. His research has contributed to advancements in understanding and treating autoimmune conditions.
Collaborations
Glickman has collaborated with notable colleagues, including Lodoe Lama and Thomas Tuschl. Their combined expertise has furthered research in the field of therapeutic agents.
Conclusion
J Fraser Glickman is a distinguished inventor whose work in developing inhibitors of cGAS has the potential to impact the treatment of autoimmune diseases significantly. His contributions to science and medicine are commendable and reflect his dedication to innovation.